[Esthesioneuroblastoma: a case report and literature review].
L. Kalala , F. Abraham , R. Gilles , F. Schils
Revue médicale de Liège 64 ( 3) 119 -123
1
2009
Sequential Administration of Epirubicin and Paclitaxel for Advanced Breast Cancer. A Phase I Randomised Trial
Guy Jerusalem , M. Beauduin , J.-P. Salmon , J. P. Lobelle
Anticancer Research 25 1211 -1217
4
2005
Circadian variation in serum concentration of carcinoembryonic antigen (CEA) is altered in cancer patients.
C. Focan , D. Focan-Henrard , G. Labrecque , Vincenzo Castronovo
PERGAMON PRESS
1
1984
Le cas clinique du mois. L'endocardite métastatique: observation clinique et revue de la littérature
Raymond Limet , P. Evrard , L. Longrée , Etienne Creemers
Revue médicale de Liège 53 ( 10) 588 -591
1
1998
Tomographie a emission de positons au 18FDG et adenocarcinome pancreatique
Frédéric Daenen , Pierre Rigo , Pierre Honore , Roland Hustinx
Revue médicale de Liège 55 ( 2) 89 -94
1
2000
Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
M. Beauduin , D. Brohee , J. Bury , M. L. Herman
Anticancer Research 20 4665 -4672
8
2000
Chronobiologie et marqueurs biochimiques du cancer humain
C. Focan
The Transactions of The Zoological Society of London 35 ( 6) 951 -959
5
1987
Chronochimiothérapie à base de 5-fluorouracil, acide folinique et oxaliplatine administrée en deux jours toutes les deux semaines pour le cancer colorectal. L’expérience du CHC-Liège (Belgique)
C. Focan , N. Moeneclaey , G. Matus , M.-P. Graas
Pathologie Biologie 61 ( 5)
1
2013
[Neoadjuvant chemotherapy, with mitoxantrone, cyclophosphamide and fluorouracil, in operable breast cancer of intermediate stage: first results of a phase II study in 40 patients].
M. Lemaire , M.T. Closon-Dejardin , Robert Paridaens , C. Desaive
Bulletin Du Cancer 79 ( 9) 883 -891
6
1992
[Tolerance of adjuvant treatment combining postoperative intraportal chemotherapy and a systemic treatment based on 5-fluorouracil in colorectal carcinoma with a histologically poor prognosis].
S. Markiewicz , B. Dallemagne , R. Lombard , C. Jehaes
Acta Gastro-enterologica Belgica 55 ( 4) 341 -349
1
1992
How to accurately evaluate growth fraction potential doubling time and cell loss in animal and human tumor systems with circadian kinetics
C. Focan
Annual review of chronopharmacology 7 215 -218
1
1990
Presentation anatomo-clinique. Terato-carcinome testiculaire avec adenopathies thoraco-abdominales
Natzi Sakalihasan , S. Dassy , J. Weerts , Céline Jehaes
Revue médicale de Liège 56 ( 11) 777 -784
2001
Leucémie aiguë non lymphoblastique survenant précocement après un carcinome pulmonaire à petites cellules
G. Franco , J. J. Claessens , C. Focan , C. Bouillenne
Presse Medicale 16 ( 28)
1987
Circadian tolerance to etoposide and cisplatin as first line treatment for advanced lung carcinoma
F. Levi , B. Bastens , J. L. Pujol , P. Mendes
Annual review of chronopharmacology 7 219 -222
4
1990
Sources of predictable tumor marker variation within the so-called normal range: circadian and circannual aspects of plasma carcinoembryonic antigen (CEA) in health and cancer
A. Auzeby , A. Bogdan , R. W. Roemeling , P. Franchimont
Journal of Tumor Marker Oncology 3 ( 4) 351 -359
6
1988
Le traitement du cancer de la prostate par les analogues de la LHRH
J. Desirotte , M. Doupagne , C. Focan , P. Franchimont
Medecine Et Hygiene 44 ( 1666) 2057 -2062
1986
Efficacité d'une chimiothérapie séquentielle incluant la vincristine, cis-platinum and ifosfamide dans le traitement des carcinomes de la tête et du cou stade IV et des mélanomes avec atteinte viscérale: résultats préliminaires
M. H. Frere , P. Mbuyamba , E. Salamon , J. J. Claessens
Bulletin Du Cancer 71 ( 2) 105 -107
1984
Phase I II M ulticenter R andomized T rial o f O xaliplatin Added t o C hronomodulated F luorouracil-Leu covorin a s First-Line T reatment o f M etastatic C olorectal C ancer
F. Bertheaut-Cvitkovic , R. Faggiuolo , C. Focan , Y. Letourneau
1,778
2000
Objective response to chemotherapy as a potential surrogate of survival in metastatic breast cancer patients.: Plus Commentary.
P. Bruzzi , L.D. Mastro , R. Rosso , J. Poul
Clinical Oncology 61 55 -63
2005
Profiling patients with high-risk myelodysplastic syndromes who prefer to receive survival prognostic information
P. Niscola , U. Platzbecker , A. Jonasova , V. Klimek
18thCongress of the European Hematology Association (EHA) 98 443 -443
2013